Onconova Therapeutics Story

Onconova Therapeutics Inc -- USA Stock  

USD 0.93  0.08  7.92%

Macroaxis does not monitor all media channels or aggregates social signals for Onconova Therapeutics. But even though we do not provide professional-grade financial sentiment analysis on Onconova Therapeutics Inc, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Onconova Therapeutics. Additionally take a look at Onconova Therapeutics Hype Analysis, Onconova Therapeutics Correlation and Onconova Therapeutics Performance
Conversion by Michael Hoffman of 140449 shares of Onconova Therapeutics
Filed transaction by Onconova Therapeutics Inc director. Derivative codes conversion of derivative security

Onconova Therapeutics Inc insider trading alert for conversion of series c convertible preferred stock by Michael Hoffman, the corporate stakeholder, on March 8, 2018. This event was filed by Onconova Therapeutics Inc with SEC on 2013-08-01. Statement of changes in beneficial ownership - SEC Form 4

Story Momentum

This media report from MacroaxisInsider distributed on March 8, 2018 was a factor to the next trading day price appreciation.The trading delta at closing time against the next closing price was 0.94% . The trading delta at closing time when the story was published against the current closing price is 3.77% .

Similar stores for Onconova Therapeutics

Green stock of the month Onconova Therapeutics, Inc. stock performed -15.57news
The Stocks News Low Wild stock to watch Onconova Therapeutics, Inc. Wallstreet InvestorplaceFull coverage
few days ago at http://huronreport.com 
Timpani Capital Management Has Boosted Merit Med Sys Com Position By 1.56 Million Last Week Onconova ...
HuronReportFull coverage
over a week ago at http://postanalyst.com 
A Preview of Valuations Summary Sanofi , Onconova Therapeutics, Inc.
Sanofi current PS is an impressive 2.27. The overall Drug Manufacturers - Major group has an average PS ratio of 6.15, which is significantly better than the sector 8.74.

Did you try this?

Run Risk-Return Analysis Now

Risk-Return Analysis

View associations between returns expected from investment and the risk you assume
Hide  View All  NextLaunch Risk-Return Analysis

Shares Outstanding

Shares Outstanding Comparative Analysis
  Shares Outstanding 
      Onconova Therapeutics Comparables 
Onconova Therapeutics is currently under evaluation in shares outstanding category among related companies. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted bases which include exotic instruments such as options, or convertibles bonds.